Nanotechnology for Drug Delivery : 2011-2021

Nanotechnology for Drug Delivery 2012

Price GBP 2499.00 / USD 4000.00

The healthcare market is poised to see some of the earliest benefits of nanotechnology. Over the next decade, it will be one of nanotech’s highest growth sectors. Targeted drug delivery therapies for the treatment of cancer is one of the most commonly cited nano-healthcare benefits. Cientifica’s report, Nanotechnology for Drug Delivery 2012, gives a comprehensive analysis and geographic breakdown of the current nanotechnology drug delivery market and its most relevant technologies. It also provides a forecast for the size of total addressable markets and percent share of those key technologies to 2021.

Some forecasts have predicted the nanotechnology market to reach close to a trillion dollars by 2015, presenting investors with unique opportunities. However, the market for applications of nanotechnology is complex, multidisciplinary and highly segmented. It is therefore essential to gain an understanding of which market sectors nanotechnology is likely to impact most profoundly in the near term.

Since we now know most (if not all) biological processes occur at the nanoscale, the application of life science principles – studying the causes of biological phenomena at the molecular level – means medical and biomedical research is increasingly using a bottom-up (rather than the top-down) approach. The low bioavailability resulting from traditional oral and intravenous drug delivery methods and the market forces at work in the pharmaceutical industry, where patents expire after a relatively short period of time unless a novel form of drug delivery is developed that will extend the patent, are two major forces that will fuel the growth of the nanotech drug delivery market. The third factor at play is a combination of improved global health and a correspondingly dramatic increase in the size of the global aging population.

This report provides insight into the possibilities of targeted nanotech drug delivery and its market potential over the next decade.

  1. I would like to
  2. (required)
  3. (valid email required)
  4. Captcha

cforms contact form by delicious:days

Table of contents 


Market Scope

This report provides an in-depth presentation of recent developments in nanotech drug delivery (NDD) and provides market opportunities to 2021, for the largest economies in the Americas, Asia, Europe and the rest of the world. Two market analyses are presented;

  • The historical market growth for NDD between 2000-2010
  • Market forecast for NDD from 2011 to 2021

Both sets of data are segmented into market by geographical region (US$ millions, % share, and compound annual growth rates by country) for America; Asia, Europe, and Rest of the World (key economies only) and by technology type (US$ millions, percent share and compound annual growth rate). Technology types examined include:

  • Solubility & Bioavailability
  • Targeted Delivery
  • Drug Nanocrystals
  • Total Nanocarriers
  • Liposomes
  • Carbon nanotubes
  • Gold Nanocarriers
  • Dendrimers
  • Micelles
  • Polymer-based Nanocarriers
  • Nanoshells
  • Ceramic Nanocarriers
  • Calcium phosphate Nanocarriers

 Table of contents 

Summary of findings (current and future)

The market growth for NDD in the period 2000-2010 shows it reached US$1,030 million by 2010.

The forecast for nanotech drug delivery to 2021  shows that the total addressable market  will reach US$ 136,134 million by 2021 and the compound annual growth rate (CAGR) is estimated to be 49.96% over the period 2010-20121.

Also included in the report is:

  • An overview of nanotechnology;
  • Identification of several key drivers for nanotechnology adoption in medicine and biomedicine;
  • The most important fields for the adoption of nanotechnology in medicine; and
  • An explanation of how nanotechnology is already having an impact on the drugs delivery sector through several relevant case studies.

In addition to an examination of general trends, Nanotechnology for Drug Delivery 2012 identifies five current & future challenges to as well as the major barriers to adoption of nanotechnology in medicine and biomedicine and provides a Technology Adoption Roadmap.

The report examines the stage of development of key nanotechnologies used in drug delivery, sorted by applications, including

  • Nanopharmaceuticals
  • Nanobiotechnology in drug delivery
  • Analytical techniques for nanoparticle drug delivery
  • Clinically approved nanocarrier-based formulations present on the market and in the pipeline
  • Clinically approved nanocrystals-based formulations present on the market and in development
  • Nanotechnology-based alternatives to nanocarriers in drug delivery
  • Present and future applications

Table of contents 


Information contained within this report is procured from several sources. These include proprietary research carried out by Cientifica, primary sources including interviews with industry and academics, and secondary sources including online publications and datasets to determine:

  • current size of pharma, drug delivery and nanotech drug delivery markets including compound annual growth rates (CAGR)
  • population sizes/growth to 2021
  • global and regional health statistics
  • patent data including expiration dates
  • pharma company mergers and acquisitions
  • company and university R&D expenditure
  • trends in governments’ healthcare spending figures including CAGR
  • current drug delivery market as percent of whole pharma market including CAGR
  • highest grossing drug delivery products currently on the market
  • drug delivery research and publication statistics.

This data is analysed to provide the current nanotech drug delivery market (2010) and global total addressable market for products for the next decade.

Companies mentioned in this report include:


Access Pharmaceuticals
AlphaRx Inc.
Amgen, Inc.
Angiotech Pharmaceuticals, Inc.
Aptalis Pharmaceutical Technologies
Biophan Technologies, Inc.
BioSante Pharmaceuticals
Calando Pharmaceuticals, Inc.
Camurus AB
Capsulution Pharma AG
Celgene Corporation
Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN)
Cephalon, Inc.
Ceramisphere Pty Ltd
Cerulean Pharma, Inc
Copernicus Therapeutics, Inc.
CritiTech, Inc.
CytImmune Sciences, Inc.
Cytokine PharmaSciences, Inc.
Debiotech SA
Elan Corporation, plc
Enzon Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd
Flamel Technologies SA
Flexible Medical Systems
IOTA NanoSolutions Ltd.
Izon Science Ltd
Kiadis Pharma
Kuecept Ltd
Lena Nanoceutics Ltd
Life Technologies
Lypro Biosciences
Makefield Therapeutics, Inc.
Medical Nanotechnologies, Inc.
Merck & Co., Inc.
Merck Serono
Merck Sharp & Dohme Corp.
Nano Interface Technology, Inc
Nano S Biotechnology
NanoBio® Corporation
NanoBioMagnetics, Inc
NanoCarrier Co. Ltd.
NanoMaterials Technology Pte Ltd
NanoSight Ltd.
Nanosphere, Inc.
Nanotherapeutics, Inc.
Nemucore Medical Innovations
nLife Therapeutics, S.L.
Novartis Institutes for Biomedical Research (NIBR)
Novartis Pharmaceuticals
Novavax, Inc.
NUCRYST Pharmaceuticals Corp.
PAR Pharmaceutical, Inc.
Particle Sciences, Inc.
PharmaNova Inc
Sigma-Tau Pharmaceuticals, Inc.
SoluBest Ltd.
Spectrum Pharmaceuticals, Inc.
Spherics, Inc.
The Dow Chemical Company (“Dow”)
VYOME Biosciences


Table of contents 




  1. I would like to
  2. (required)
  3. (valid email required)
  4. Captcha

cforms contact form by delicious:days